Obesity-related Chronic Kidney Disease (Ob-CKD) encompasses a wide range of manifestations in persons with chronic kidney disease (CKD), from cases without known structural damage (hyperfiltration or albuminuria) to more advanced stages with obesity-related glomerulopathy (glomerular hypertrophy, podocytopathy, mesangial matrix expansion, focal and segmental glomerulosclerosis, tubulointerstitial fibrosis, tubular atrophy, and vascular lesions). Ob-CKD can also coexist with other kidney diseases, affect persons on dialysis, and in kidney transplant recipients.
In response to this complexity,
Spanish Society of Nephrology (S.E.N.), Latin American Society of Nephrology
and Hypertension (SLANH), and Spanish Society for the Study of Obesity (SEEDO)
developed a consensus report proposing a classification system based on renal
alterations and CKD stage (non-dialysis, dialysis, or transplant), aiming to
standardize terminology and guide clinical management. One of our principal aims is to diagnose
individuals with obesity and CKD, classify, and subsequently individualize
their treatment. What remains undiagnosed will remain untreated.
The effective treatment of Ob-CKD
requires a multidisciplinary approach involving nutritional therapy, physical
activity, pharmacological treatment, and bariatric surgery when indicated. The
consensus also emphasizes the role of incretin-based therapies, which have been
shown to promote weight loss and improve cardiorenal outcomes, including
reductions in cardiovascular events and mortality in persons with Ob-CKD.
This was published in Kidney International
See a sample below of cases related to Ob-CKD
Guest Post by
No comments:
Post a Comment